Role of N6-methyladenosine methylation related gene IGF2BP3 in renal clear cell carcinoma
10.3969/j.issn.1673-4130.2025.01.007
- VernacularTitle:N6-甲基腺苷甲基化相关基因IGF2BP3在肾透明细胞癌的作用研究
- Author:
Xianzhong WANG
1
;
Zhong WANG
;
Dapeng HE
;
Yaming LAI
;
Wenya AN
;
Zugang SUN
;
Xisong XIE
;
Chunxiang WU
Author Information
1. 广元市中心医院泌尿外科,四川广元 628000
- Keywords:
renal clear cell carcinoma;
N6-methyladenosine;
insulin-like growth factor 2 mRNA bind-ing protein 3;
migration;
invasion
- From:
International Journal of Laboratory Medicine
2025;46(1):27-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To screen the key N6-methyladenosine(m6A)methylation related genes in renal clear cell carcinoma(ccRCC),and to study their expression and relationship with the prognosis,migration and invasion of renal clear cell carcinoma.Methods The RNA sequencing data and clinical data of ccRCC and ad-jacent tissues were downloaded from the Cancer Genome Atlas(TCGA)and GTEx(Genotype-Tissue Expres-sion).The expression profile and prognosis were analyzed with R 4.1.1,and the key genes were screened.Clinical specimens of 10 patients with ccRCC were collected.The mRNA and protein expressions were detec-ted by RT-qPCR and immunohistochemistry,respectively.In human ccRCC cell line RCC23,siRNA was used to knock down key genes,and CCK-8 was used to detect the survival rate of cells.Scratch test and Trans well test were used to detect the migration and invasion of cells,respectively.Results Among the 19 m6A methyl-ation related genes,only insulin-like growth factor 2 mRNA binding protein 3(IGF2BP3)was highly ex-pressed in cancer tissues,and the high expression was significantly positively correlated with poor prognosis.The high expression of IGF2BP3 was verified in clinical specimens by RT-qPCR and immunohistochemistry.After knockdown of IGF2BP3 by siRNA,the survival rate of RCC23 cells decreased significantly,and the mi-gration and invasion ability of cut cells decreased.Conclusion These results suggest that IGF2BP3 may be an effective biomarker and potential drug target for predicting the prognosis of patients with ccRCC.
